BDX240816C285000
- 0.05
- 0.000.00%
Becton Dickinson & Co Newsroom
U.S. to Restart Free COVID Test Program as Cases Spike
(BDX) - Analyzing Becton Dickinson's Short Interest
Least Shorted S&P 500 Stocks in July
The 20 Most Popular Mutual Fund Increases During 2Q - Goldman Sachs
Express News | Hhs: Recommend Health Care Providers Prioritize & Conserve BD Bactec Blood Culture Media Bottles per FDA's Recommendations
Express News | Hhs: Aware of Disruptions in the Availability of BD Bactec Blood Culture Media Bottles
Wells Fargo Maintains Becton Dickinson & Co(BDX.US) With Buy Rating, Maintains Target Price $280
Moderna Was the Most Shorted S&P 500 Healthcare Stock in July
Analyzing Becton, Dickinson and Company (BDX) Among Top Dividend Aristocrats of 2024
Argus Research Cuts Price Target on Becton, Dickinson to $290 From $300, Buy Rating Maintained
Express News | BD Names Michael Feld as President of Life Sciences Segment
BD to Present at Wells Fargo 2024 Healthcare Conference
Looking Into Becton Dickinson's Recent Short Interest
Is Becton, Dickinson and Company (BDX) a Good Organ Transplant and Diagnosis Stock to Buy Right Now?
The Past Year for Becton Dickinson (NYSE:BDX) Investors Has Not Been Profitable
Becton Dickinson Analyst Ratings
BofA Securities Maintains Becton Dickinson & Co(BDX.US) With Buy Rating
Raymond James Maintains Becton Dickinson & Co(BDX.US) With Buy Rating, Cuts Target Price to $270
Stifel Maintains Becton Dickinson & Co(BDX.US) With Buy Rating, Maintains Target Price $280
A Quick Look at Today's Ratings for Becton Dickinson & Co(BDX.US), With a Forecast Between $260 to $312